Home

Ron Squarer

CIK 1454001 · CEO · last filed 2026-07-15

Ron Squarer is a CEO who has filed 55 SEC Form 4 insider transactions across 6 companies since 2009. The most recent filing, for NUVL, was dated Jul 15, 2026. Across all open-market trades the lifetime net is −$1.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.8M across reported positions. 20 SEC filings were submitted jointly with ARRAY BIOPHARMA INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.75M

Companies

6

Total Filings

55

Lifetime Open-Market Net

-$1.72M

Filer Profile

Reported Address
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130
Related Filers
ARRAY BIOPHARMA INC — 20 joint filings, latest 2019-07-30
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
Nuvalent, Inc. (NUVL) Delisted Director 0 $123.96 $0 $0 3 2026-07-15
ADCT Director 138,627 $1.07 $148.3K -$20.2K 5 2026-06-03
TVTX Director 39,375 $66.17 $2.61M $0 6 2026-05-21
Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Director — $25.59 — $0 12 2024-06-11
Travere Therapeutics, Inc. (RTRX) Delisted Director 11,875 — — $0 4 2020-05-19
HOSPIRA INC (HSP) Delisted Chief Commercial Officer 19,563 — — -$1.70M 6 2011-02-28

Recent Filings

55 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-15 Nuvalent, Inc. (NUVL) Delisted Disp (D) −6,281 $0 EDGAR
2026-06-18 Nuvalent, Inc. (NUVL) Delisted Grant (A) +3,444 $0 EDGAR
2026-06-03 ADCT Mixed +29,804 -$46.8K EDGAR
2026-05-21 TVTX Grant (A) +4,000 $0 EDGAR
2025-12-11 Nuvalent, Inc. (NUVL) Delisted Grant (A) +2,837 $0 EDGAR
2025-06-17 ADCT Tax (F) −15,184 -$54.4K EDGAR
2025-06-05 ADCT Grant (A) +40,000 $0 EDGAR
2025-05-16 TVTX Grant (A) +6,500 $0 EDGAR
2024-06-18 ADCT Sell (S) −6,995 -$20.2K EDGAR
2024-06-18 ADCT Notice (144) −6,995 -$20.2K EDGAR
Showing 1–10 of 55
Page 1 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.